share_log

Risks To Shareholder Returns Are Elevated At These Prices For Shandong Sino-Agri United Biotechnology Co.,Ltd (SZSE:003042)

山東省シノアグリ・ユナイテッドバイオテクノロジー株式会社(SZSE:003042)の株主のリターンに対するリスクはこれらの価格で高まっています。

Simply Wall St ·  02/09 07:40

With a median price-to-sales (or "P/S") ratio of close to 1.7x in the Chemicals industry in China, you could be forgiven for feeling indifferent about Shandong Sino-Agri United Biotechnology Co.,Ltd's (SZSE:003042) P/S ratio of 1.2x. However, investors might be overlooking a clear opportunity or potential setback if there is no rational basis for the P/S.

ps-multiple-vs-industry
SZSE:003042 Price to Sales Ratio vs Industry February 8th 2024

What Does Shandong Sino-Agri United BiotechnologyLtd's Recent Performance Look Like?

For instance, Shandong Sino-Agri United BiotechnologyLtd's receding revenue in recent times would have to be some food for thought. It might be that many expect the company to put the disappointing revenue performance behind them over the coming period, which has kept the P/S from falling. If not, then existing shareholders may be a little nervous about the viability of the share price.

We don't have analyst forecasts, but you can see how recent trends are setting up the company for the future by checking out our free report on Shandong Sino-Agri United BiotechnologyLtd's earnings, revenue and cash flow.

How Is Shandong Sino-Agri United BiotechnologyLtd's Revenue Growth Trending?

In order to justify its P/S ratio, Shandong Sino-Agri United BiotechnologyLtd would need to produce growth that's similar to the industry.

Taking a look back first, the company's revenue growth last year wasn't something to get excited about as it posted a disappointing decline of 8.7%. Regardless, revenue has managed to lift by a handy 14% in aggregate from three years ago, thanks to the earlier period of growth. Accordingly, while they would have preferred to keep the run going, shareholders would be roughly satisfied with the medium-term rates of revenue growth.

Comparing that to the industry, which is predicted to deliver 26% growth in the next 12 months, the company's momentum is weaker, based on recent medium-term annualised revenue results.

In light of this, it's curious that Shandong Sino-Agri United BiotechnologyLtd's P/S sits in line with the majority of other companies. Apparently many investors in the company are less bearish than recent times would indicate and aren't willing to let go of their stock right now. They may be setting themselves up for future disappointment if the P/S falls to levels more in line with recent growth rates.

What We Can Learn From Shandong Sino-Agri United BiotechnologyLtd's P/S?

Using the price-to-sales ratio alone to determine if you should sell your stock isn't sensible, however it can be a practical guide to the company's future prospects.

We've established that Shandong Sino-Agri United BiotechnologyLtd's average P/S is a bit surprising since its recent three-year growth is lower than the wider industry forecast. When we see weak revenue with slower than industry growth, we suspect the share price is at risk of declining, bringing the P/S back in line with expectations. Unless the recent medium-term conditions improve, it's hard to accept the current share price as fair value.

You always need to take note of risks, for example - Shandong Sino-Agri United BiotechnologyLtd has 2 warning signs we think you should be aware of.

If strong companies turning a profit tickle your fancy, then you'll want to check out this free list of interesting companies that trade on a low P/E (but have proven they can grow earnings).

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする